LogicBio Therapeutics (OTCMKTS:LOGC) Shares Up 0.3% – What’s Next?

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC)’s stock price rose 0.3% during trading on Monday. The stock traded as high as $15.35 and last traded at $15.14. 154,009 shares were traded during mid-day trading, an increase of 60% from the average session volume of 95,956 shares. The stock had previously closed at $15.10.

LogicBio Therapeutics Price Performance

The stock has a market cap of $692.35 million, a PE ratio of -20.74 and a beta of 2.04. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.87 and a quick ratio of 1.24. The business has a fifty day moving average of $13.70 and a 200 day moving average of $10.64.

LogicBio Therapeutics (OTCMKTS:LOGC) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10). The business had revenue of $33.60 million during the quarter, compared to analysts’ expectations of $33.60 million.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics was a clinical-stage genetic medicine company focused on developing therapies for patients with severe genetic diseases. The company’s research centered on its GeneRide platform, an approach designed to support the targeted insertion of therapeutic genes into the genome and potentially provide durable treatment after a single administration.

LogicBio’s lead investigational program was LB-001, an experimental gene therapy for methylmalonic acidemia, a rare inherited metabolic disorder that primarily affects children.